Innova Captab Stock Screener | Share Price & Fundamental Analysis
INNOVACAP
Pharmaceuticals
Screen Innova Captab share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹730.95
▼
-2.25 (-0.31%)
Share Price BSE
₹728.20
▼
-1.90 (-0.26%)
Market Cap
₹4,114.76 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.96
EPS (TTM)
₹22.41
Dividend Yield
-
Debt to Equity
0.33
52W High
₹1187.70
52W Low
₹668.55
Operating Margin
15.00%
Profit Margin
9.43%
Revenue (TTM)
₹318.00
EBITDA
₹51.00
Net Income
₹30.00
Total Assets
₹1,580.00
Total Equity
₹959.00
Innova Captab Share Price History - Stock Screener Chart
Screen INNOVACAP historical share price movements with interactive charts. Analyze price trends and patterns.
Innova Captab Company Profile - Fundamental Screener
Screen Innova Captab company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for INNOVACAP shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0DUT01020
Innova Captab Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen INNOVACAP balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 1,580 | 1,321 | 704 | 576 | 370 | 245 | 0 |
| Current Assets | 696 | 580 | 443 | 379 | 271 | 171 | 0 |
| Fixed Assets | 830 | 358 | 183 | 183 | 79 | 73 | 0 |
| Liabilities | |||||||
| Total Liabilities | 1,580 | 1,321 | 704 | 576 | 370 | 245 | 0 |
| Current Liabilities | 268 | 225 | 150 | 72 | 10 | 14 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 959 | 831 | 277 | 209 | 145 | 110 | 0 |
| Share Capital | 57 | 57 | 48 | 12 | 12 | 12 | 0 |
| Reserves & Surplus | 902 | 774 | 229 | 197 | 133 | 98 | 0 |
Screen INNOVACAP income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 318 | 356 | 385 | 268 | 296 | 320 | 321 | 244 | 234 | 286 | 305 | 217 | 244 | 245 |
| Expenses | 267 | 299 | 329 | 225 | 252 | 269 | 270 | 214 | 202 | 243 | 258 | 197 | 211 | 208 |
| EBITDA | 51 | 57 | 56 | 44 | 44 | 52 | 51 | 29 | 32 | 44 | 47 | 21 | 33 | 37 |
| Operating Profit % | 15.00% | 15.00% | 14.00% | 15.00% | 14.00% | 16.00% | 15.00% | 11.00% | 13.00% | 14.00% | 15.00% | 9.00% | 13.00% | 14.00% |
| Depreciation | 10 | 11 | 11 | 3 | 5 | 5 | 5 | 3 | 3 | 5 | 5 | 3 | 3 | 3 |
| Interest | 2 | 3 | 6 | 1 | 0 | 0 | 0 | 5 | 5 | 9 | 7 | 3 | 5 | 6 |
| Profit Before Tax | 39 | 43 | 39 | 40 | 39 | 47 | 46 | 21 | 25 | 30 | 35 | 15 | 25 | 28 |
| Tax | 10 | 12 | 10 | 11 | 10 | 12 | 11 | 4 | 7 | 7 | 10 | 2 | 6 | 9 |
| Net Profit | 30 | 31 | 30 | 29 | 30 | 35 | 34 | 17 | 18 | 23 | 25 | 13 | 19 | 20 |
| EPS | 5.17 | 5.42 | 5.18 | 5.02 | 5.15 | 6.12 | 5.97 | 3.59 | 3.67 | 4.77 | 4.39 | 108.91 | 3.91 | 4.08 |
Innova Captab Cash Flow Screener - Liquidity Fundamentals
Screen INNOVACAP cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 64 | 146 | 67 | 59 | 42 | 31 | 19 |
| Investing Activities | -152 | -499 | -91 | -188 | -20 | -6 | -9 |
| Financing Activities | 92 | 361 | 27 | 125 | -19 | -23 | -9 |
| Net Cash Flow | 4 | 8 | 3 | -5 | 3 | 2 | 1 |
Screen INNOVACAP shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% |
| FII Holding | 0.34% | 0.23% | 0.08% | 1.94% | 1.19% | 1.01% | 0.74% | 0.00% |
| DII Holding | 19.76% | 19.67% | 20.17% | 20.77% | 21.23% | 20.61% | 19.96% | 11.73% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 27.62% | 27.71% | 27.35% | 25.47% | 25.80% | 26.00% | 26.96% | 32.10% |
| Other Holding | 1.37% | 1.49% | 1.50% | 0.91% | 0.88% | 1.48% | 1.45% | 5.26% |
| Shareholder Count | 39,996 | 41,014 | 40,245 | 39,396 | 35,115 | 32,254 | 36,692 | 139,154 |
Innova Captab Dividend Screener - Share Yield Analysis
Screen INNOVACAP dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Innova Captab Index Membership - Market Screener Classification
Screen INNOVACAP by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Innova Captab Market Events Screener - Corporate Actions
Screen INNOVACAP market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 16.12% | ||
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -1.75% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 3.01% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 8.82% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 9.28% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 12.54% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 13.66% |
Innova Captab Competitors Screener - Peer Comparison
Screen INNOVACAP competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.30 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.25 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 59.98 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.21 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.46 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.85 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.09 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.78 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.36 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 27.28 | 13,458 | 3.70% | 2,216 | 37.45 |
Innova Captab Company Announcements - News Screener
Screen INNOVACAP latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Closure of Trading Window | View |
| 2025-12-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-07 | Approval Of The Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended 30Th September 2025. | View |
| 2025-11-07 | Mr. Devendra Ganpatrav Palav Who Currently Serves As The Chief Executive Officer (CEO) Of Sharon Bio-Medicine Limited A Material Subsidiary Of The Company Has Been Redesignated As Manager In Addition To His Existing Role As CEO. | View |
| 2025-11-07 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 07Th November 2025 | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-30 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR)Regulations 2015 For Consideration Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended 30Th September 2025. | View |
| 2025-10-20 | Recommendation Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control. | View |
| 2025-10-16 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-16 | Pursuant To Regulation 30 Read With Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) We Hereby Inform You That M/S. CARE Ratings Limited A Credit Rating Agency Has Revised The Cre | View |
| 2025-08-21 | Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (The Listing Regulations). | View |
| 2025-08-20 | Pursuant To The Regulation 30 (Read With Part A Of Schedule III) And Other Applicable Provisions Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) We Hereby Inform That The Company Has Successfully Completed | View |